These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 29945960)

  • 1. Upregulation of E3 Ubiquitin Ligase CBLC Enhances EGFR Dysregulation and Signaling in Lung Adenocarcinoma.
    Hong SY; Kao YR; Lee TC; Wu CW
    Cancer Res; 2018 Sep; 78(17):4984-4996. PubMed ID: 29945960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stabilization of AURKA by the E3 ubiquitin ligase CBLC in lung adenocarcinoma.
    Hong SY; Lu YC; Hsiao SH; Kao YR; Lee MH; Lin YP; Wang CY; Wu CW
    Oncogene; 2022 Mar; 41(13):1907-1917. PubMed ID: 35149839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL.
    Tan YC; Mirzapoiazova T; Won BM; Zhu L; Srivastava MK; Vokes EE; Husain AN; Batra SK; Sharma S; Salgia R
    Sci Rep; 2017 Aug; 7(1):9192. PubMed ID: 28835699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ubiquitin ligase Cbl-b is involved in icotinib (BPI-2009H)-induced apoptosis and G1 phase arrest of EGFR mutation-positive non-small-cell lung cancer.
    Mu X; Zhang Y; Qu X; Hou K; Kang J; Hu X; Liu Y
    Biomed Res Int; 2013; 2013():726375. PubMed ID: 23586056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.
    Giordano F; Vaira V; Cortinovis D; Bonomo S; Goedmakers J; Brena F; Cialdella A; Ianzano L; Forno I; Cerrito MG; Giovannoni R; Ferri GL; Tasciotti E; Vicent S; Damarco F; Bosari S; Lavitrano M; Grassilli E
    J Exp Clin Cancer Res; 2019 Jun; 38(1):260. PubMed ID: 31200752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma.
    Ito M; Codony-Servat C; Codony-Servat J; Lligé D; Chaib I; Sun X; Miao J; Sun R; Cai X; Verlicchi A; Okada M; Molina-Vila MA; Karachaliou N; Cao P; Rosell R
    Cell Commun Signal; 2019 Oct; 17(1):137. PubMed ID: 31660987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced Glycolysis Supports Cell Survival in EGFR-Mutant Lung Adenocarcinoma by Inhibiting Autophagy-Mediated EGFR Degradation.
    Kim JH; Nam B; Choi YJ; Kim SY; Lee JE; Sung KJ; Kim WS; Choi CM; Chang EJ; Koh JS; Song JS; Yoon S; Lee JC; Rho JK; Son J
    Cancer Res; 2018 Aug; 78(16):4482-4496. PubMed ID: 29945964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppressed expression of Cbl-b by NF-κB mediates icotinib resistance in EGFR-mutant non-small-cell lung cancer.
    Zhang T; Zheng C; Hou K; Wang J; Zhang Y; Fan Y; Zhao H; Qu X; Liu Y; Kang J; Che X; Hu X
    Cell Biol Int; 2019 Feb; 43(2):98-107. PubMed ID: 29972257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric ubiquitin ligases inhibit non-small cell lung cancer via negative modulation of EGFR signaling.
    Zhong D; Ru Y; Wang Q; Zhang J; Zhang J; Wei J; Wu J; Yao L; Li X; Li X
    Cancer Lett; 2015 Apr; 359(1):57-64. PubMed ID: 25573345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting CDC34 E2 ubiquitin conjugating enzyme for lung cancer therapy.
    Zhang S; Sun Y
    EBioMedicine; 2020 Apr; 54():102718. PubMed ID: 32268269
    [No Abstract]   [Full Text] [Related]  

  • 11. LncRNA DUXAP9-206 directly binds with Cbl-b to augment EGFR signaling and promotes non-small cell lung cancer progression.
    Zhu T; An S; Choy MT; Zhou J; Wu S; Liu S; Liu B; Yao Z; Zhu X; Wu J; He Z
    J Cell Mol Med; 2019 Mar; 23(3):1852-1864. PubMed ID: 30515972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Negative regulation of EGFR-Vav2 signaling axis by Cbl ubiquitin ligase controls EGF receptor-mediated epithelial cell adherens junction dynamics and cell migration.
    Duan L; Raja SM; Chen G; Virmani S; Williams SH; Clubb RJ; Mukhopadhyay C; Rainey MA; Ying G; Dimri M; Chen J; Reddi AL; Naramura M; Band V; Band H
    J Biol Chem; 2011 Jan; 286(1):620-33. PubMed ID: 20940296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leukocyte Cell-Derived Chemotaxin 2 Retards Non-Small Cell Lung Cancer Progression Through Antagonizing MET and EGFR Activities.
    Hung WY; Chang JH; Cheng Y; Chen CK; Chen JQ; Hua KT; Cheng CW; Hsiao M; Chung CL; Lee WJ; Chien MH
    Cell Physiol Biochem; 2018; 51(1):337-355. PubMed ID: 30453282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction between two ubiquitin-protein isopeptide ligases of different classes, CBLC and AIP4/ITCH.
    Courbard JR; Fiore F; Adélaïde J; Borg JP; Birnbaum D; Ollendorff V
    J Biol Chem; 2002 Nov; 277(47):45267-75. PubMed ID: 12226085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The E3 ubiquitin ligase NEDD4 mediates cell migration signaling of EGFR in lung cancer cells.
    Shao G; Wang R; Sun A; Wei J; Peng K; Dai Q; Yang W; Lin Q
    Mol Cancer; 2018 Feb; 17(1):24. PubMed ID: 29455656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse Model.
    Martin P; Stewart E; Pham NA; Mascaux C; Panchal D; Li M; Kim L; Sakashita S; Wang D; Sykes J; Friess T; Shepherd FA; Liu G; Tsao MS
    Clin Lung Cancer; 2016 Sep; 17(5):375-383.e2. PubMed ID: 26926157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. USP22 promotes resistance to EGFR-TKIs by preventing ubiquitination-mediated EGFR degradation in EGFR-mutant lung adenocarcinoma.
    Zhang H; Han B; Lu H; Zhao Y; Chen X; Meng Q; Cao M; Cai L; Hu J
    Cancer Lett; 2018 Oct; 433():186-198. PubMed ID: 29981430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
    Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
    Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of the Aryl Hydrocarbon Receptor Leads to Resistance to EGFR TKIs in Non-Small Cell Lung Cancer by Activating Src-mediated Bypass Signaling.
    Ye M; Zhang Y; Gao H; Xu Y; Jing P; Wu J; Zhang X; Xiong J; Dong C; Yao L; Zhang J; Zhang J
    Clin Cancer Res; 2018 Mar; 24(5):1227-1239. PubMed ID: 29229632
    [No Abstract]   [Full Text] [Related]  

  • 20. Low expression of the E3 ubiquitin ligase CBL confers chemoresistance in human pancreatic cancer and is targeted by epidermal growth factor receptor inhibition.
    Kadera BE; Toste PA; Wu N; Li L; Nguyen AH; Dawson DW; Donahue TR
    Clin Cancer Res; 2015 Jan; 21(1):157-65. PubMed ID: 25348515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.